NCT01138722

Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial

Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: University Hospital, Ghent · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.

Conditions

• Early Stage Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	hypofractionated radiation therapy followed by surgery	hypofractionated radiation therapy followed by surgery

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2010-06-07
• Last updated: 2021-07-08

Locations

2 sites across 1 country: Belgium